VCYT Q2 2018 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M+23.6% YoY

Gross Profit

$15M63.8% margin

Operating Income

-$6M-26.0% margin

Net Income

-$6M-27.5% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+13.5%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$4M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$65M

Total Liabilities

$40M

Stockholders' Equity

$26M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$18M	+23.6%
Gross Profit	$15M	$11M	+26.7%
Operating Income	-$6M	-$7M	+10.5%
Net Income	-$6M	-$7M	+14.4%